HIV drug resistance is a significant challenge in the management of HIV infections, and its impact is further compounded when co-infections are present. Co-infections, such as Tuberculosis (TB), hepatitis B or C, and other opportunistic infections, complicate HIV treatment regimens, often requiring careful balancing of multiple medications. These co-infections can lead to drug-drug interactions, altered pharmacokinetics, and a higher risk of adverse effects, all of which can accelerate the development of HIV drug resistance. Managing HIV in patients with co-infections requires a nuanced understanding of both HIV pathogenesis and the characteristics of the coinfecting diseases. One of the major difficulties in managing HIV in the context of co-infection is the need for combination therapies that address both the HIV infection and the co-infecting pathogen. For instance, Tuberculosis (TB) is one of the most common co-infections seen in people living with HIV, particularly in regions with high rates of TB prevalence.
HTML PDFShare this article
Journal of AIDS & Clinical Research received 5264 citations as per Google Scholar report